We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+19.11%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$196M
AUM Growth
+$25.4M
Cap. Flow
+$6.53M
Cap. Flow %
3.33%
Top 10 Hldgs %
68.13%
Holding
55
New
16
Increased
5
Reduced
7
Closed
19

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$15.5M
2
GSK icon
GSK
GSK
+$12.8M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$7.3M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$7.13M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$3.64M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$14.4M
2
AZN icon
AstraZeneca
AZN
+$8.73M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.09M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.18M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$4.64M

Sector Composition

Rank Sector Weight
1 Healthcare 70.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PFE icon
1
Pfizer
PFE
$140B
$26.9M 13.7%
827,444
+492,218
+147% +$15.5M
SHPG
2
DELISTED
Shire pic
SHPG
$18.1M 9.25%
104,000
-26,000
-20% -$4.54M
AZN icon
3
CALL
AstraZeneca
AZN
$263B
$15.3M 7.79%
245,000
+120,000
+96% +$6.99M
CELG
4
DELISTED
Celgene Corp
CELG
$14.9M 7.62%
120,000
-2,000
-2% -$239K
GSK icon
5
GSK
GSK
$103B
$13.3M 6.81%
+253,200
New +$12.8M
VRTX icon
6
CALL
Vertex Pharmaceuticals
VRTX
$121B
$10.9M 5.58%
+100,000
New +$8.8M
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$10.5M 5.35%
86,500
-13,500
-14% -$1.74M
KITE
8
DELISTED
Kite Pharma, Inc.
KITE
$8.24M 4.21%
105,000
-45,000
-30% -$2.78M
TSRO
9
PUT
DELISTED
TESARO, Inc.
TSRO
$7.69M 3.93%
50,000
– –
NDRM
10
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$7.65M 3.9%
+288,000
New +$7.13M
GBT
11
DELISTED
Global Blood Therapeutics, Inc.
GBT
$7.54M 3.85%
204,500
+144,500
+241% +$3.64M
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$312M
$7.17M 3.66%
+512,200
New +$7.3M
ARRY
13
CALL
DELISTED
Array Biopharma Inc
ARRY
$7.15M 3.65%
+800,000
New +$8.51M
NERV icon
14
Minerva Neurosciences
NERV
$188M
$6.13M 3.13%
94,650
+33,030
+54% +$2.57M
LUMO
15
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$4.82M 2.46%
22,222
– –
ACRS icon
16
Aclaris Therapeutics
ACRS
$730M
$3.33M 1.7%
+111,500
New +$3.21M
EIGR
17
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.02M 1.54%
8,787
– –
PRTK
18
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$2.89M 1.47%
150,000
+50,000
+50% +$788K
RXDX
19
DELISTED
Ignyta, Inc.
RXDX
$2.88M 1.47%
+335,000
New +$2.45M
ABEO icon
20
Abeona Therapeutics
ABEO
$345M
$2.47M 1.26%
19,763
-2,980
-13% -$384K
TVRD
21
Tvardi Therapeutics
TVRD
$23.5M
$2.21M 1.13%
3,333
-3,611
-52% -$1.93M
AXSM icon
22
Axsome Therapeutics
AXSM
$12.4B
$1.56M 0.8%
+400,000
New +$1.91M
SIOX
23
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.49M 0.76%
12,500
– –
TIG
24
DELISTED
TiGenix American Depositary Shares
TIG
$1.44M 0.73%
+92,203
New +$1.38M
MRNS
25
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.42M 0.72%
+200,000
New +$1.07M
1
2 3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Nexthera Capital held 55 positions worth $196M, up 15% from $171M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Nexthera Capital deployed $6.53M of net new capital in Q1 2017, opening 16 new positions and adding to 5 existing holdings. Its largest new stake was GSK: 253,200 shares worth $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 83% a quarter earlier.

On the sell side, the largest reduction was Shire pic, an estimated $4.54M trimmed.

  • Nexthera Capital's largest Q1 2017 buy was GSK: 253,200 shares worth $13.3M.
  • Nexthera Capital added most to Pfizer in Q1 2017, an estimated $15.5M increase.
  • Nexthera Capital's biggest Q1 2017 reduction was Shire pic, cutting an estimated $4.54M.
  • Nexthera Capital fully exited Novartis in Q1 2017, selling an estimated $14.4M.
  • Nexthera Capital's ten largest holdings make up 68% of its $196M portfolio in Q1 2017.
  • Nexthera Capital opened 16 new positions and closed 19 in Q1 2017.
  • Nexthera Capital's portfolio value rose 15% quarter-over-quarter to $196M.

Based on Nexthera Capital's 13F filing for Q1 2017, filed 15 May 2017.